Search

Displaying results 5471 - 5480 of 5496 in total
  1. Drug

    OCU400

    go.drugbank.com/drugs/DB18277
    Investigational

    OCU400 is a novel gene therapy comprising an adeno-associated viral vector expressing human nuclear hormone receptor subfamily 2 group E member 3 (hNR2E3).

  2. Drug

    Satricabtagene autoleucel

    go.drugbank.com/drugs/DB18288
    Investigational

    Satricabtagene autoleucel is an autologous CAR T-cell product candidate against protein Claudin18.2 (CLDN18.2).

  3. Drug

    CTB001

    go.drugbank.com/drugs/DB18316
    Investigational

    CTB001 is an anti-claudin 18.2 autologous chimeric antigen receptor (CAR) T-cell therapy under investigation for the treatment of gastric cancers.[L48146]

  4. Drug

    LIS-1

    go.drugbank.com/drugs/DB18388
    Experimental

    LIS-1 is an immunoglobulin G (IgG) polyclonal antibody that binds to human T cells.

  5. Drug

    LAVA-051

    go.drugbank.com/drugs/DB18395
    Investigational

    LAVA-051 is a humanized Vγ9Vδ2-T cell-engaging bispecific antibody.

  6. Drug

    Zilovertamab vedotin

    go.drugbank.com/drugs/DB18457
    Investigational

    conjugate (ADC) comprising an anti-ROR1 monoclonal antibody (UC-961), a proteolytically cleavable maleimidocaproyl-valine-citrulline-para-aminobenzoate linker (mc-vc-PAB), and a monomethyl auristatin E

  7. Drug

    ISB 2001

    go.drugbank.com/drugs/DB18570
    Investigational

    ISB 2001 is a T cell-engaging antibody that targets BCMA, CD38, and CD3.

  8. Drug

    ECT204

    go.drugbank.com/drugs/DB18605
    Investigational

    ECT204 is an autologous T-cell therapy whereby T cells are genetically modified to target tumor-specific antigens.

  9. Drug

    Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen

    go.drugbank.com/drugs/DB18661
    Approved

    This defense includes the production of humoral immunity through the development of antibodies and of cell-mediated immunity through the production of T-lymphocytes.

  10. Drug

    BG1805

    go.drugbank.com/drugs/DB18667
    Investigational

    BG1805 is an investigational anti-CLL1 chimeric antigen receptor (CAR) T-cell therapy.